Latest press releases
- AstraZeneca’s new restructuring initiatives to drive productivity and support innovation
- 2 February 2012
- AstraZeneca PLC Fourth quarter and full year results 2011
- 2 February 2012
- AstraZeneca and Bristol-Myers Squibb receive complete response letter from US Food and Drug Administration for dapagliflozin
- 19 January 2012
- AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
- 11 January 2012
- AstraZeneca reaffirms December 2011 financial guidance for 2011 and mid-term planning assumptions for the 2010 to 2014 period
- 9 January 2012
- AstraZeneca updates on olaparib and TC-5214 development programmes
- 20 December 2011
- G-BA issues positive final medical benefit assessment for BRILIQUE in Germany
- 15 December 2011
- AstraZeneca to acquire generics company to broaden patient access to medicines in China
- 8 December 2011
- AstraZeneca to streamline US sales organisation
- 7 December 2011
Executive biographies
Louis Schweitzer is our Board Chair. He was appointed to this position on 11 March 2004.
Our Chief Executive Officer is David Brennan. He was appointed to this position on 1 January 2006.
AstraZeneca tweets
-
AZ #infection scientist published in Nature Reviews Drug Discovery on economic incentives to create new #antibiotics http://t.co/2o3wBYuR
12 hours ago -
VIDEO: Tony Zook, EVP Commercial, discusses key brands and customer-facing initiatives http://t.co/2sCScV0q
2 Feb -
VIDEO: R&D President Mackay discusses R&D performance and productivity http://t.co/Af7eBz1v
2 Feb
Fast facts
AstraZeneca is a global, innovation-driven biopharmaceutical business. We focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.
Our innovative medicines are used by millions of patients worldwide.